S&P 500   3,206.29 (-0.63%)
DOW   26,719.23 (-0.56%)
S&P 500   3,206.29 (-0.63%)
DOW   26,719.23 (-0.56%)
S&P 500   3,206.29 (-0.63%)
DOW   26,719.23 (-0.56%)
S&P 500   3,206.29 (-0.63%)
DOW   26,719.23 (-0.56%)
Log in

NASDAQ:CBPOChina Biologic Products Stock Price, Forecast & News

$107.28
+0.73 (+0.69 %)
(As of 07/16/2020 08:56 AM ET)
Add
Compare
Today's Range
$106.09
Now: $107.28
$107.89
50-Day Range
$101.98
MA: $107.39
$110.77
52-Week Range
$92.22
Now: $107.28
$119.44
Volume122,200 shs
Average Volume136,921 shs
Market Capitalization$4.22 billion
P/E Ratio27.16
Dividend YieldN/A
Beta0.82
China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.
Read More
China Biologic Products logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.69 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CBPO
CUSIPN/A
Phone86-10-6598-3111

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$503.70 million
Cash Flow$4.95 per share
Book Value$45.09 per share

Profitability

Net Income$138.81 million

Miscellaneous

Employees2,269
Market Cap$4.22 billion
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive CBPO News and Ratings via Email

Sign-up to receive the latest news and ratings for CBPO and its competitors with MarketBeat's FREE daily newsletter.

China Biologic Products (NASDAQ:CBPO) Frequently Asked Questions

How has China Biologic Products' stock been impacted by COVID-19 (Coronavirus)?

China Biologic Products' stock was trading at $115.86 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CBPO shares have decreased by 7.4% and is now trading at $107.28. View which stocks have been most impacted by Coronavirus.

When is China Biologic Products' next earnings date?

China Biologic Products is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for China Biologic Products.

How were China Biologic Products' earnings last quarter?

China Biologic Products Holdings Inc (NASDAQ:CBPO) released its earnings results on Wednesday, May, 20th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, topping analysts' consensus estimates of $1.38 by $0.18. The biopharmaceutical company earned $162.59 million during the quarter. China Biologic Products had a return on equity of 10.01% and a net margin of 28.80%. During the same period in the prior year, the firm posted $1.11 earnings per share. View China Biologic Products' earnings history.

Has China Biologic Products been receiving favorable news coverage?

Media stories about CBPO stock have been trending positive on Thursday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. China Biologic Products earned a coverage optimism score of 2.1 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news about China Biologic Products.

Are investors shorting China Biologic Products?

China Biologic Products saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 454,300 shares, an increase of 6.6% from the June 15th total of 426,300 shares. Based on an average daily volume of 118,600 shares, the days-to-cover ratio is currently 3.8 days. Approximately 2.3% of the company's stock are sold short. View China Biologic Products' Current Options Chain.

Who are some of China Biologic Products' key competitors?

What other stocks do shareholders of China Biologic Products own?

Based on aggregate information from My MarketBeat watchlists, some companies that other China Biologic Products investors own include Lexicon Pharmaceuticals (LXRX), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Advanced Micro Devices (AMD), Amgen (AMGN), Biogen (BIIB) and Micron Technology (MU).

Who are China Biologic Products' key executives?

China Biologic Products' management team includes the following people:
  • Mr. Ming Yang, Chief Financial Officer (Age 47)
  • Mr. Ming Yin, Sr. VP (Age 41)
  • Ms. Zhijing Liu, Corp. VP (Age 65)
  • Mr. Gang Yang, Corp. VP & GM of Guizhou Taibang (Age 54)
  • Dr. Bing Li Ph.D., CEO & Director (Age 51)

What is China Biologic Products' stock symbol?

China Biologic Products trades on the NASDAQ under the ticker symbol "CBPO."

How do I buy shares of China Biologic Products?

Shares of CBPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is China Biologic Products' stock price today?

One share of CBPO stock can currently be purchased for approximately $107.28.

How big of a company is China Biologic Products?

China Biologic Products has a market capitalization of $4.22 billion and generates $503.70 million in revenue each year. The biopharmaceutical company earns $138.81 million in net income (profit) each year or $4.28 on an earnings per share basis. China Biologic Products employs 2,269 workers across the globe.

What is China Biologic Products' official website?

The official website for China Biologic Products is www.chinabiologic.com.

How can I contact China Biologic Products?

China Biologic Products' mailing address is 18TH FL JIALONG INTERNATIONALBUILDING 19 CHAOYANG PARK ROAD CHAOYANG DISTRICT, BEIJING F4, 100125. The biopharmaceutical company can be reached via phone at 86-10-6598-3111 or via email at [email protected]

This page was last updated on 7/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.